Physician profile
Istvan Redei
NPI 1306818109
$5,108.24
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,757 · 2020: $341 · 2021: $422 · 2022: $2,354 · 2023: $235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $235.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $235.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $1,600.00 | 2022 | |
| Beigene USA, INC. | $678.57 | 2021-2023 | Brukinsa |
| Novartis Pharmaceuticals Corporation | $372.17 | 2019-2021 | |
| Seagen INC. | $319.91 | 2019-2022 | |
| Celgene Corporation | $261.51 | 2019-2023 | Pomalyst |
| Pfizer INC. | $236.00 | 2019-2020 | |
| Janssen Biotech, INC. | $228.91 | 2019-2021 | |
| Amgen INC. | $227.13 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $220.13 | 2021-2023 | Calquence |
| Genentech USA, INC. | $142.49 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $99.88 | 2019-2021 | |
| Astellas Pharma US INC | $95.00 | 2019 | |
| Verastem, INC. | $83.14 | 2019-2020 | |
| Adaptive Biotechnologies Corporation | $56.56 | 2021 | |
| Cti Biopharma Corp. | $44.24 | 2022-2023 | Vonjo |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $41.12 | 2019 | |
| Merck Sharp & Dohme LLC | $40.00 | 2019-2023 | |
| Pharmacyclics LLC, An Abbvie Company | $34.80 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.76 | 2019 | |
| Aurobindo Pharma USA, INC. | $33.66 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $28.88 | 2019 | |
| Genzyme Corporation | $24.77 | 2021 | |
| Karyopharm Therapeutics INC. | $24.16 | 2020 | |
| Epizyme, INC. | $23.05 | 2021 | |
| Abbvie INC. | $22.39 | 2019 | |
| Adc Therapeutics America, INC. | $22.02 | 2022 | |
| Kyowa Kirin, INC. | $18.86 | 2019 | |
| Abbott Laboratories | $18.01 | 2020 | |
| Clovis Oncology, INC. | $17.43 | 2019 | |
| Morphosys, US INC. | $17.37 | 2021 | |
| Incyte Corporation | $15.47 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.43 | 2020 | |
| Gilead Sciences, INC. | $11.42 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Istvan Redei listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.